Table of contents
Trial overview
The available trial data describe one interventional study, LOTUS, investigating ARGININE GLUTAMATE in the setting of chronic hemodialysis.[1] The study is looking at muscle protein turnover, which means how the body builds and breaks down muscle protein over time.[1]
The brief summary says the study is designed to see the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to characterize the hemodynamic effects of IDPN.[1]
Study design and phase
LOTUS is listed as a Phase 3 study, which means it is a later-stage clinical trial.[1] It is also described as an interventional study, so researchers are giving a treatment and then measuring its effects.[1]
The trial status is Authorised, and the planned enrollment is 20 participants.[1] The intervention is listed as a drug combination given parenterally, which means by a route that does not use the digestive tract.[1]
Who is being studied
The target population is people receiving hemodialysis.[1] The trial data do not provide additional inclusion or exclusion rules, so the only clearly stated group is chronic hemodialysis patients.[1]
This focus matters because the study is not looking at a general healthy population; it is aimed at a specific patient group with kidney failure treated by dialysis.[1]
What is being measured
The main endpoint is the difference in myofibrillar fractional synthetic rate during one week of treatment with IDPN versus control.[1] This is a research measure of how quickly muscle fibers are making new protein.[1]
The study also aims to describe the hemodynamic effects of IDPN, meaning changes related to blood flow and circulation.[1] Together, these outcomes show that the trial is looking at both muscle-related and circulation-related effects in the dialysis setting.[1]
Trial summary
In the trial record, the study title is LOTUS.[1] The condition fields list muscle protein turnover and hemodialysis, and the brief summary explains that the goal is to study muscle protein synthesis and hemodynamic effects in chronic hemodialysis patients.[1]
The single available study is small, with 20 planned participants, and it is already authorised.[1] Based on the source data, this trial is mainly a focused research study in a specific dialysis population rather than a broad study across many diseases.[1]
